Chemycal has been acquired by 3E
Learn MoreChemycal has been acquired by 3E
Learn More
Discover how Chemycal PRO helps you boosting your regulatory monitoring:
The Minutes of the Working Group Meeting on Cosmetic Ingredients includes the folllowing items:
New mandates or information from DG GROW
(*) Benzophenone-1
(*) Benzophenone-4
(*) Methylparaben
(*) OCM
(*) Salicylic Acid
Draft Opinions discussed
(*) Genistein: the draft preliminary Opinion has been discussed and tasks have been allocated to members. It is planned to be finalised during the next December meeting.
(*) Daidzein: the draft preliminary Opinion has been discussed and tasks have been allocated to members. It is planned to be finalised during the next December meeting.
(*) Revision of the Vitamin A Opinion: the draft preliminary Opinion has been finalised and will go through written procedure for adoption before the next December meeting.
(*) Aluminium (aggregate exposure): the draft preliminary Opinion has been presented and tasks have been allocated to members. A new request for clarification to the Applicant is under preparation.
(*) 4-Methylbenzylidene camphor (4-MBC): the draft preliminary Opinion has been discussed and tasks have been allocated to members. It is planned to be finalised during the next December meeting.
(*) Scientific Advice on Triclocarban and Triclosan: the draft document has been presented and will be further discussed at the next December meeting.
(*) Scientific Advice on Homosalate: the draft document has been finalised and will be adopted by written procedure after the meeting.
(*) Arbutins: the draft preliminary Opinion has been discussed and tasks have been allocated to members. It will be further discussed at the next December meeting.
Comments on Opinions
(*) The final Opinion on fragrance Methylsalicylate was published: Opinion of the Scientific Committee on Consumer Safety on Methyl salicylate (methyl 2-hydroxybenzoate) (europa.eu)
(*) A corrigendum on Lawsonia inermis (Henna) - SCCS/1511/13 was published sccs_o_140.pdf (europa.eu) Corrigenda made in the Opinion: Page 19: Percutaneous absorption in vitro. DAp of 4.08 % to be used for MoS calculation. Page 22: NOAEL of 2 mg/kg bw/d will be used for the MoS. Page 37: Revision of the calculation of the Margin of Safety (MoS) from 210 to 156. Page 39: Discussion on dermal absorption: DAp revised from 5.3% to 4.08%.
(*) The preliminary Opinion on kojic acid has been published for comment until 14 January 2022: SCCS - Opinions 2016 - 2021 | Public Health (europa.eu)
(*) Prostaglandins and prostaglandin-analogues used in cosmetic products - SCCS/1635/21: the comments received have been presented during the WG and will be further discussed in the next December meeting, together with some expected additional information.
(*) Butylated Hydroxytoluene (BHT) - SCCS/1636/21: the comments received have been discussed and the SCCS prepared their response. The final Opinion (unchanged), together with the SCCS response document will be adopted by written procedure after the meeting.
CONTINUE READING ON ec.europa.eu
2013 © MyChemicalMonitoring. ALL Rights Reserved. About Us | Terms and Conditions